Equities

LeMaitre Vascular Inc

LeMaitre Vascular Inc

Actions
  • Price (EUR)70.00
  • Today's Change0.00 / 0.00%
  • Shares traded250.00
  • 1 Year change+16.67%
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024 07:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Company’s principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.

  • Revenue in USD (TTM)199.89m
  • Net income in USD33.95m
  • Incorporated1998
  • Employees614.00
  • Location
    LeMaitre Vascular Inc63 2nd AveBURLINGTON 01803-4413United StatesUSA
  • Phone+1 (781) 221-2266
  • Fax+1 (781) 425-5049
  • Websitehttps://www.lemaitre.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.